<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028713</url>
  </required_header>
  <id_info>
    <org_study_id>BIOLOPTIM-ADA</org_study_id>
    <nct_id>NCT04028713</nct_id>
  </id_info>
  <brief_title>Dose Tapering Study of Adalimumab in Psoriasis</brief_title>
  <official_title>A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal therapeutic serum trough level (Ctrough) of adalimumab was defined between 3,5
      and 7,0 Âµg/ml in patients with plaque type psoriasis. An adalimumab Ctrough above this
      therapeutic range did not add clinical response. Based on this therapeutic window, the
      introduction of dose adjustments based on Ctroughs (therapeutic drug monitoring) will be
      further validated in a prospective randomized-controlled trial. Here, we aim to determine
      whether, in patients with a good clinical response and supratherapeutic adalimumab Ctroughs,
      dose reduction is able to maintain favorable clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be included after signing informed consent and randomized in either a standard
      dose arm or a concentration based arm based on prior Ctrough measurements. In the
      concentration based arm, dosing frequency will be lowered to once every 3 weeks. If patients
      still have supratherapeutic Ctroughs of adalimumab, these patients will continue adalimumab
      self-administration every 4 weeks. In the standard based arm, patients will continue on
      standard dosing schedule. During each study visit blood will be taken in order to quantify
      Ctroughs. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global
      Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology
      Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit. In
      addition, in a subset of patients in each treatment arm, additional sampling will be
      collected by dried blood spot sampling in order to build a PK(PD) model for adalimumab.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized non-inferiority study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 0- Week 48</time_frame>
    <description>The proportion of patients in each group in clinical remission (absolute PASI &lt; 2) at year 1 after optimization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in each group with serum trough levels of adalimumab within the optimal interval.</measure>
    <time_frame>Week 0- Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in each group with anti-drug antibodies (ADA) against adalimumab.</measure>
    <time_frame>Week 0- Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>Week 0- Week 48</time_frame>
    <description>The proportion of patients in each group who relapses (defined as the need for dose escalation (not in the standard based dosing arm))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Standard dosing group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will continue to receive adalimumab according to the standard dosing schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose tapering group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Venapuncture</intervention_name>
    <description>Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.</description>
    <arm_group_label>Dose tapering group</arm_group_label>
    <arm_group_label>Standard dosing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dried blood spot</intervention_name>
    <description>A subset of patients will sample additionally by using the dried blood sampling technique.</description>
    <arm_group_label>Dose tapering group</arm_group_label>
    <arm_group_label>Standard dosing group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose reduction</intervention_name>
    <description>Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.</description>
    <arm_group_label>Dose tapering group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must have a clinical or histological diagnosis of chronic plaque-type
             psoriasis for at least 6 months prior to inclusion

          2. Participants must have a stable disease during maintenance on adalimumab (absolute
             PASI &lt; 3)

          3. Participants are not allowed to use topical steroids from 7 days before randomization
             until the end of the study (week 48).

          4. Participants must sign an ICF indicating that he or she understands the purpose of,
             and procedures required for, the study and is willing to participate in the study

        Exclusion Criteria:

          1. Participants who have currently a predominant nonplaque form of psoriasis

          2. Participants who are pregnant, nursing or planning a pregnancy while enrolled in the
             study or within 12 weeks after receiving the last administration of study intervention

          3. Participants who are unable or unwilling to undergo multiple venapunctures

          4. Participants who are treated according to a different dosing schedule than standard
             dosing of adalimumab (regular dose regimen every 2 weeks; 40 mg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Lambert, Prof, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jo Lambert, Prof, dr</last_name>
    <phone>09 332 22 87</phone>
    <phone_ext>+32</phone_ext>
    <email>jo.lambert@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynda Grine, Dr</last_name>
    <phone>09 332 22 87</phone>
    <phone_ext>+32</phone_ext>
    <email>lynda.grine@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Linda Temmerman, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Ghent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence Dierckxsens, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jo Lambert, Prof</last_name>
      <phone>09332287</phone>
      <phone_ext>+32</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Lynda Grine, Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Private practice Dermatology</name>
      <address>
        <city>Maldegem</city>
        <state>East-Flanders</state>
        <zip>9990</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Sven Lanssens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Tom Hillary, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta Rembert</name>
      <address>
        <city>Torhout</city>
        <state>West-Flanders</state>
        <zip>8820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Annelies Stockman, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marleen Goeteyn, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

